Article Information
History
- October 18, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Otavio T Ranzani, PhD1,2,
- Rogério dos Santos Leite, MD3,
- Larissa Domingues Castilho, PT4,
- Crhistinne Cavalheiro Maymone Gonçalves, PhD4,5,
- Geraldo Resende, MD4,
- Rosana Leite de Melo, MD6 and
- Julio Croda, PhD5,7,8,*
- 1Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain
- 2Pulmonary Division, Heart Institute (InCor), Hospital das Clinicas (HCFMUSP), Faculdade de Medicina da Universidade de São Paulo, Brazil
- 3Secretaria Municipal de Saúde de Corumbá, Corumbá, Brazil
- 4Secretaria de Saúde do estado de Mato Grosso do Sul, Campo Grande, Brazil
- 5Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil
- 6Secretaria Extraordinária de Enfrentamento à Covid-19, Ministério da Saúde, Brasília, Brazil
- 7Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, USA
- 8Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, Brazil
- ↵*Correspondence to: Prof Julio Croda, Universidade Federal de Mato Grosso do Sul and Fundação Oswaldo Cruz, julio.croda{at}fiocruz.br
Posted October 18, 2021.
Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design
